You are here: Industry Insights > HBV

News List

R&D Milestone: HebaBiz Biotech's application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved prnasia
November 16, 2021
HebaBiz Biotech is pleased to announce that in November 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) of China has approved the application...
MIMETAS and Roche Enter into a Collaboration to Develop Human Disease Models for Drug Development b3cnewswire
July 07, 2021
MIMETAS announced today that they have entered into a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV).
CaroGen, BioCentriq Enter Clinical Manufacturing Pact contractpharma
June 23, 2021
BioCentriq to provide clinical manufacturing to support Phase 1 clinical trials of CaroGen's lead immunotherapy candidate, CARG-201.
Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients firstwordpharma
June 23, 2021
Enanta Pharmaceuticals, Inc. today announced positive data from the first two dose cohorts of its Phase 1b study of EDP-514 in viremic chronic HBV patients who were not being treated with a nucleoside reverse transcriptase inhibitor (NUC).
Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology prnasia
June 21, 2021
Innovent Biologics, Inc. today announced that data from the ORIENT-32 study have been published in The Lancet Oncology.
Vemlidy(r) Demonstrates Continued Efficacy and Improved Safety for Asian Patients with Hepatitis B prnasia
February 04, 2021
Gilead Sciences announced today at the 2021 Asian Pacific Association for the Study of the Liver Conference (APASL), findings from two sub-analyses that demonstrated the continued efficacy and improved safety of Vemlidy® ...
Vaccitech Doses First Patient in HBV002 for Chronic HBV americanpharmaceuticalreview
February 04, 2021
Vaccitech announced the dosing of the first patient in HBV002. HBV002 is a Phase 1b/2a clinical trial designed to evaluate the safety and preliminary efficacy of VTP-300 both with and without a low-dose anti-PD-1 antibody in patients with CHB infection.
Antios Completes Phase 1b Clinical Trial of ATI-2173 for Chronic Hepatitis B Virus Infection americanpharmaceuticalreview
January 26, 2021
Antios Therapeutics has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with chronic hepatitis B virus (HBV) infection.
Gilead and Vir unite to find a ‘functional cure’ for hepatitis B pharmatimes
January 15, 2021
Gilead Sciences and Vir Biotechnology have partnered to evaluate novel therapeutic combination strategies aimed at developing a ‘functional cure’ for chronic hepatitis B virus (HBV).
Assembly Biosciences to Wind-Down Microbiome Program americanpharmaceuticalreview
December 30, 2020
Assembly Biosciences will wind-down its microbiome program, enabling the company to prioritize resources and focus on the advancement of its pipeline of novel core inhibitors for chronic hepatitis B virus (HBV).

Previous page 1 2 3 Next page